-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The top five causes of blindness among the elderly in China are: cataract, age-related macular degeneration, diabetic retinopathy (DR), corneal disease, and glaucoma.
DR has tripled in the past 10 years
.
Recently, the "Chinese Clinical Guidelines for the Prevention and Treatment of Type 2 Diabetes in the Elderly (2022 Edition)" was released.
Regarding diabetic retinopathy (DR) and blindness, the guidelines mainly involve the following contents
.
Guideline points Comprehensive eye examination should be carried out every year to detect lesions in time and start treatment as soon as possible (B, I)
.
Good control of blood sugar, blood pressure and blood lipids can prevent or delay the progression of DR (A, I)
.
Patients with nonproliferative DR of moderate or higher macular edema should be further managed by an ophthalmologist with relevant knowledge and experience (A, I)
.
Diabetic retinopathy (DR) is a complication unique to diabetes that can begin in prediabetes
.
Poor blood sugar and blood pressure control, poor life>
.
Among elderly diabetic patients, the prevalence of DR in post-senior diabetic patients (12%) was much lower than that in pre-senior diabetic patients (>24%), and the risk of blindness due to aging-related and diabetes-related macular degeneration was significantly increased
.
Cataracts and glaucoma are also important causes of blindness and vision loss in elderly diabetic patients who lack lens replacement conditions
.
Therefore, elderly patients with diabetes should undergo annual ophthalmological examinations (vision, intraocular pressure, fundus) and retinopathy screening, and if conditions permit, routinely perform non-mydriatic fundus photography and optical coherence tomography (OCT) screening every year to detect early retina in time.
For diseases such as macular edema and macular edema, early initiation of treatment has the greatest benefit in reducing the rate of blindness
.
There were no age differences in the stages of development and diagnostic criteria for DR and macular edema
.
Patients with macular edema and moderate or greater nonproliferative DR should be further managed by an ophthalmologist with knowledge and experience in DR management
.
Table 1 International clinical classification of diabetic retinopathy (2002) Table 2 Diabetic macular edema classification (2002) Correction of unhealthy life>
.
For patients with moderate or above lesions, it is also possible to reduce the risk of blindness by striving for the control of various metabolic indicators to meet the standards
.
For elderly diabetic patients with impaired multi-organ function, high risk of hypoglycemia, and limited life expectancy, the criteria should be relaxed, and attention should be paid to the balance between the benefits of eye disease and the occurrence of serious cardiovascular events
.
After the development of severe non-proliferative retinopathy, laser photocoagulation therapy is an effective measure to prevent blindness, supplemented by improving microcirculation (calcium dobesilate, kallikrein) and anti-inflammatory therapy
.
Fenofibrate slows DR progression and reduces the need for laser therapy
.
Intravitreal injection of anti-vascular endothelial growth factor (VEGF) is indicated for the treatment of moderate or greater diabetic macular edema to reduce the risk of blindness
.
Some studies have shown that bevacizumab is better than ranibizumab and aflibercept in the treatment of diabetes-related and age-related macular edema
.
Specialist treatment of cataract and glaucoma in elderly diabetic patients should be more aggressive
.
The above content is excerpted from: China Clinical Guidelines for the Prevention and Treatment of Type 2 Diabetes in the Elderly, China Geriatrics Association Geriatric Endocrinology and Metabolism Branch, China Geriatrics Medical Research Association Geriatric Endocrinology and Metabolism Branch, etc.
Chinese Clinical Guidelines for the Prevention and Treatment of Type 2 Diabetes in the Elderly (2022 Edition) [J].
Chinese Journal of Internal Medicine, 2022, 61(01): 12-50.
DR has tripled in the past 10 years
.
Recently, the "Chinese Clinical Guidelines for the Prevention and Treatment of Type 2 Diabetes in the Elderly (2022 Edition)" was released.
Regarding diabetic retinopathy (DR) and blindness, the guidelines mainly involve the following contents
.
Guideline points Comprehensive eye examination should be carried out every year to detect lesions in time and start treatment as soon as possible (B, I)
.
Good control of blood sugar, blood pressure and blood lipids can prevent or delay the progression of DR (A, I)
.
Patients with nonproliferative DR of moderate or higher macular edema should be further managed by an ophthalmologist with relevant knowledge and experience (A, I)
.
Diabetic retinopathy (DR) is a complication unique to diabetes that can begin in prediabetes
.
Poor blood sugar and blood pressure control, poor life>
.
Among elderly diabetic patients, the prevalence of DR in post-senior diabetic patients (12%) was much lower than that in pre-senior diabetic patients (>24%), and the risk of blindness due to aging-related and diabetes-related macular degeneration was significantly increased
.
Cataracts and glaucoma are also important causes of blindness and vision loss in elderly diabetic patients who lack lens replacement conditions
.
Therefore, elderly patients with diabetes should undergo annual ophthalmological examinations (vision, intraocular pressure, fundus) and retinopathy screening, and if conditions permit, routinely perform non-mydriatic fundus photography and optical coherence tomography (OCT) screening every year to detect early retina in time.
For diseases such as macular edema and macular edema, early initiation of treatment has the greatest benefit in reducing the rate of blindness
.
There were no age differences in the stages of development and diagnostic criteria for DR and macular edema
.
Patients with macular edema and moderate or greater nonproliferative DR should be further managed by an ophthalmologist with knowledge and experience in DR management
.
Table 1 International clinical classification of diabetic retinopathy (2002) Table 2 Diabetic macular edema classification (2002) Correction of unhealthy life>
.
For patients with moderate or above lesions, it is also possible to reduce the risk of blindness by striving for the control of various metabolic indicators to meet the standards
.
For elderly diabetic patients with impaired multi-organ function, high risk of hypoglycemia, and limited life expectancy, the criteria should be relaxed, and attention should be paid to the balance between the benefits of eye disease and the occurrence of serious cardiovascular events
.
After the development of severe non-proliferative retinopathy, laser photocoagulation therapy is an effective measure to prevent blindness, supplemented by improving microcirculation (calcium dobesilate, kallikrein) and anti-inflammatory therapy
.
Fenofibrate slows DR progression and reduces the need for laser therapy
.
Intravitreal injection of anti-vascular endothelial growth factor (VEGF) is indicated for the treatment of moderate or greater diabetic macular edema to reduce the risk of blindness
.
Some studies have shown that bevacizumab is better than ranibizumab and aflibercept in the treatment of diabetes-related and age-related macular edema
.
Specialist treatment of cataract and glaucoma in elderly diabetic patients should be more aggressive
.
The above content is excerpted from: China Clinical Guidelines for the Prevention and Treatment of Type 2 Diabetes in the Elderly, China Geriatrics Association Geriatric Endocrinology and Metabolism Branch, China Geriatrics Medical Research Association Geriatric Endocrinology and Metabolism Branch, etc.
Chinese Clinical Guidelines for the Prevention and Treatment of Type 2 Diabetes in the Elderly (2022 Edition) [J].
Chinese Journal of Internal Medicine, 2022, 61(01): 12-50.
